Synapse - Paul Russo

Search Within

Paul Russo

Results (2)

Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

Meeting Abstract

Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)

Meeting Abstract

Bex, A.; Grünwald, V.; Russo, P.; Tomita, Y.; Berghorn, E.; McHenry, M. B.; Motzer, R. J.
Annals of Oncology (2018)

Fulltext@MSK | Save